In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side ...

Annual out-of-pocket treatment costs for multiple sclerosis increased by 125% from 2002 to 2021 in the US, driven mainly by newer disease-modifying therapies, a study shows.

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

A single dose of Immutep’s MS therapy, IMP761, was well tolerated and reduced T-cell activity for up to 23 days in healthy ...

With the President, political loyalty goes only one way.

Responding to a lack of sensitive analytical methods for detecting associated medications in complex wastewater matrices, ...

Liking, wanting, and craving cannabis come from genetics, stress vulnerability, and the desire to "treat" depression, anxiety ...

What began as a court hearing focused on medication for a murder suspect quickly expanded into broader questions about ...

A clinical trial testing whether music therapy can make botulinum toxin injections for spasticity more comfortable is ...

The agreement will lower the cost of certain drugs for asthma, some cancers, HIV and Type 2 diabetes, among other conditions.